Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor
- PMID: 9715276
- DOI: 10.1038/sj.onc.1201994
Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor
Abstract
Ron (the receptor for Macrophage Stimulating Protein) has never been implicated before in human malignancies or in cell transformation. In this report we show that Ron can acquire oncogenic potential by means of two amino acid substitutions-D1232V and M1254T-affecting highly conserved residues in the tyrosine kinase domain. The same mutations in Kit and Ret have been found associated with two human malignancies, mastocytosis and Multiple Endocrine Neoplasia type 2B (MEN2B), respectively. Both mutations caused Ron-mediated transformation of 3T3 fibroblasts and tumour formation in nude mice. Moreover, cells transformed by the oncogenic Ron mutants displayed high metastatic potential. The Ron mutant receptors were constitutively active and the catalytic efficiency of the mutated kinase was higher than that of wild-type Ron. Oncogenic Ron mutants enhanced activation of the Ras/MAPK cascade with respect to wild type Ron, without affecting the JNK/SAPK pathway. Expression of Ron mutants in 3T3 fibroblasts led to different patterns of tyrosine-phos-phorylated proteins. These data show that point mutations altering catalytic properties and possibly substrate specificity of the Ron kinase may force cells toward tumorigenesis and metastasis.
Similar articles
-
The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site.Oncogene. 2000 Oct 26;19(45):5208-11. doi: 10.1038/sj.onc.1203819. Oncogene. 2000. PMID: 11064459
-
Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret.Oncogene. 1998 May 14;16(19):2435-45. doi: 10.1038/sj.onc.1201778. Oncogene. 1998. PMID: 9627110
-
Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.Oncogene. 2001 Sep 27;20(43):6142-51. doi: 10.1038/sj.onc.1204836. Oncogene. 2001. PMID: 11593422
-
Oncogenic signaling pathways activated by RON receptor tyrosine kinase.Curr Cancer Drug Targets. 2003 Feb;3(1):31-40. doi: 10.2174/1568009033333745. Curr Cancer Drug Targets. 2003. PMID: 12570659 Review.
-
Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.Oncogene. 1998 Sep 17;17(11 Reviews):1343-52. doi: 10.1038/sj.onc.1202171. Oncogene. 1998. PMID: 9779982 Review.
Cited by
-
Metastatic breast carcinoma to bone disguised by osteopoikilosis.Skeletal Radiol. 2003 Apr;32(4):240-3. doi: 10.1007/s00256-002-0605-x. Epub 2003 Feb 13. Skeletal Radiol. 2003. PMID: 12652341
-
SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma.Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12032-7. doi: 10.1073/pnas.211026798. Epub 2001 Sep 25. Proc Natl Acad Sci U S A. 2001. PMID: 11572935 Free PMC article.
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.Cancer Biol Ther. 2011 Jul 1;12(1):9-46. doi: 10.4161/cbt.12.1.15747. Epub 2011 Jul 1. Cancer Biol Ther. 2011. PMID: 21543897 Free PMC article.
-
Ron receptor tyrosine kinase signaling as a therapeutic target.Expert Opin Ther Targets. 2012 Sep;16(9):921-31. doi: 10.1517/14728222.2012.710200. Epub 2012 Jul 26. Expert Opin Ther Targets. 2012. PMID: 22834780 Free PMC article. Review.
-
Protein phosphatase 1 binds to phospho-Ser-1394 of the macrophage-stimulating protein receptor.Biochem J. 2003 Dec 15;376(Pt 3):587-94. doi: 10.1042/BJ20030391. Biochem J. 2003. PMID: 14505491 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials